SmartTRAK spoke with the Westbrook Weaver, CEO of Tempo Therapeutics, to discuss the company’s new technology, how it works and the results of the clinical work they’ve completed so far.
In the wound care space, there has always been an unmet need for a product that can provide volumetric wound filling in addition to simply closing the wound. Tempo Therapeutics is looking to utilize microporous annealed particle technology, or MAP, to address this need. In an interview with SmartTRAK, Westbrook Weaver, PhD, President and CEO of Tempo Therapeutics introduces their technology for creating a three-dimensional scaffold.
To learn more about Tempo Therapeutics, click on the following video (16:41 min). A link to download a complete transcript of the interview is also provided below.
Interview Transcript:
Hi, I'm Jay Merkel with SmartTRAK. I'm here with Westbrook Weaver, the founder and CEO of Tempo Therapeutics. In full disclosure, Westbrook and I have worked together before, but for our viewers, can you tell me about your background?
Westbrook Weaver: Absolutely, Jay. And thank you for the opportunity to speak with you today. So, my name is Westbrook. I am the co-founder and the chief executive officer at Tempo Therapeutics, which is a startup-phase biotechnology biomaterials company based in San Diego, California. My background is actually as a PhD scientist. So, I got my PhD in biomedical engineering at University of California, Los Angeles, just up the road. Focused on tissue engineering and biotechnology. And during my time as a postdoctoral scholar after that, while I was still at UCLA, was in the right place at the right time with the right folks to be a co-inventor on the technology that we then ended up spinning Tempo out of UCLA around that technology, that technology is a biomaterials technology we call MAP technology.
Okay. Tell me what MAP stands for and how it is different from other flowables in the marketplace?
WW: Absolutely. So, I'm going to, for just pictorial purposes, share my screen with you as I kind of walk through this. MAP stands for microporous annealed particle technology. And it's supposed to be something that is self-descriptive, but it is a flowable, fully synthetic, hydrogel-based scaffold. But it's very unique in that it is made up of ...
Want to learn more about Tempo's new technology, how it works and the results of the clinical work they’ve completed so far? Click the button below to download and read the complete transcript of our interview with Westbrook Weaver, CEO, conducted by Jay Merkel, SmartTRAK Sr Analyst, Wound.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
